Review in Protein & cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Xiaoting HouDepartment of Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.ORCID 0009-0007-7649-4122
Yu ChenDepartment of Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.
Bo ZhouDepartment of Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.ORCID 0000-0003-4213-726X
Fengting LiuDepartment of Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.ORCID 0009-0007-1350-2420
Lingyun DaiDepartment of Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.ORCID 0000-0001-9386-5967
Chunbo ChenDepartment of Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.
Noah D CarrilloDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, United States.
Vincent L CrynsDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, United States.ORCID 0000-0003-0355-2268
Richard A AndersonUniversity of Wisconsin Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, United States.ORCID 0000-0001-6265-8359
Jichao SunDepartment of Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.ORCID 0000-0002-7671-2157
Mo ChenDepartment of Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.ORCID 0000-0002-3274-5889
Funding
Phosphoinositide Signaling in the Cytosol and NucleusR35GM134955 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Richard A. Anderson · 2020 to 2026
$5.0M
Regulation of Nuclear Akt by p53, MDM2 and Phosphoinositide Lipids Roles in Oncogenic Transformation and Tumor ProgressionR01CA286492 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Richard A. Anderson, VINCENT L. CRYNS · 2024 to 2026
$2.8M
Guangdong Province Basic and Applied Basic Research Foundation 2023A1515110237Guangdong Zhujiang Program 0920220233National Natural Science Foundation of China 32400577National Natural Science Foundation of China 82071193NCI NIH HHS R01 CA286492NIGMS NIH HHS R35 GM134955Science and Technology Foundation of Shenzhen City JCYJ20220818102611025Science and Technology Foundation of Shenzhen City RCYX20210706092040044Shenzhen Medical Research Fund D2301007Shenzhen Natural Science Foundation JCYJ20240813094605008
6 · The paper itself
Abstract
Dysregulation of p53 and phosphoinositide (PIPn) signaling are both key drivers of oncogenesis and metastasis. Our recent findings reveal a previously unrecognized interaction between these pathways, converging in the nucleus to form a PIPn-p53 signalosome that modulates nuclear AKT activation and downstream signaling, thereby influencing cancer cell survival and motility. This review examines recent insights into nuclear PIPn signaling in the context of established roles for p53 in cell dynamics and migration while also deliberating current research on how nuclear PIPns interact with p53 to form signalosomes that affect cell motility. We emphasize the critical role of PIPns in stabilizing p53 and activating de novo nuclear AKT signaling, which subsequently modulates key motility-related pathways. Understanding the unique operation and function of the PIPn-p53 signalosome in nuclear phosphatidylinositol 3-kinase (PI3K)-AKT activation offers novel therapeutic strategies for controlling cancer metastasis by targeting pertinent interactions and events.
Indexed as
Cell MovementCell NucleusNeoplasmsPhosphatidylinositolsSignal TransductionTumor Suppressor Protein p53AnimalsHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesPhosphatidylinositolsProto-Oncogene Proteins c-aktTumor Suppressor Protein p53cell motilitynucleusp53phosphoinositidesignalosome
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The nuclear phosphoinositide-p53 signalosome in the regulation of cell motility. · full record | OpenQuestion